Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.
暂无分享,去创建一个
R. Kolhe | S. Fulzele | N. Sahajpal | A. Mondal | P. Ahluwalia | Kimya Jones | V. Kota | Jordi Cortés | A. Vashisht | M. M. Galvis | Harmanpreet Singh | Danielle Bradshaw | Comfort Prah | Jaspreet Farmaha | Ryan Bloomquist | Caroline Marie Carlock | Drew Fransoso | Christina Sun | Tyler Day | Trinh Vuong | Patty Ray | Girindra Raval | Justin Xavier Moore | Jeffrey N James
[1] D. Contopoulos-Ioannidis,et al. Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis , 2023, International Journal of Infectious Diseases.
[2] Jin Zhang,et al. Immunology of SARS-CoV-2 infection and vaccination , 2023, Clinica chimica acta; international journal of clinical chemistry.
[3] J. Fantini,et al. Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies , 2023, Pathogens.
[4] C. Heaney,et al. SARS-CoV-2 Antibody Prevalence among Industrial Livestock Operation Workers and Nearby Community Residents, North Carolina, 2021 to 2022 , 2023, mSphere.
[5] Zahra A. Premji,et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression , 2023, The Lancet Infectious Diseases.
[6] M. Weekes,et al. Demographic, behavioural and occupational risk factors associated with SARS-CoV-2 infection in UK healthcare workers: a retrospective observational study , 2022, BMJ Open.
[7] A. Ghaemmaghami,et al. Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals , 2022, Scientific Reports.
[8] J. Gonzalez,et al. Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations , 2022, Viruses.
[9] David A. Jolliffe,et al. Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK) , 2022, Vaccines.
[10] T. Zewotir,et al. Identifying Potential Factors Associated with High HIV viral load in KwaZulu-Natal, South Africa using Multiple Correspondence Analysis and Random Forest Analysis , 2022, BMC Medical Research Methodology.
[11] E. Boerwinkle,et al. Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey , 2022, The Journal of infectious diseases.
[12] P. Bochud,et al. Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19 , 2022, Viruses.
[13] D. McGovern,et al. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis , 2022, BMJ Open.
[14] Wan-zhou Xu,et al. Dynamic changes of serum SARS-CoV-2 antibody levels in COVID-19 patients , 2022, Journal of Infection.
[15] J. Lambert,et al. Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms , 2022, Open forum infectious diseases.
[16] V. Calvez,et al. Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation , 2022, Frontiers in Immunology.
[17] S. Haslett,et al. Creating symptom-based criteria for diagnostic testing: a case study based on a multivariate analysis of data collected during the first wave of the COVID-19 pandemic in New Zealand , 2021, BMC Infectious Diseases.
[18] E. Kabagambe,et al. Prevalence, Distribution and IgG Antibody Levels Associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Health-System and Community-Based Employees and Patients , 2021, The American Journal of the Medical Sciences.
[19] M. Secrest,et al. Factors associated with COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective cohort study using electronic health records from the USA , 2021, BMJ Open.
[20] G. Gao,et al. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021 , 2021, International immunology.
[21] D. Wang,et al. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice , 2021, Military Medical Research.
[22] J. Tanne. Covid-19: FDA approves Pfizer-BioNTech vaccine in record time , 2021, BMJ.
[23] A. Walker,et al. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.
[24] Eleanor L. Ross,et al. An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] C. Knabbe,et al. SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study , 2021, Vaccine.
[26] Tangchun Wu,et al. Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection , 2021, Cellular & Molecular Immunology.
[27] C. Di Resta,et al. Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects , 2021, Vaccine.
[28] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[29] D. Altmann,et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.
[30] M. Hegde,et al. Clinical Validation of a Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for Severe Acute Respiratory Syndrome Coronavirus 2 Mass Surveillance , 2021, The Journal of Molecular Diagnostics.
[31] Mark Hopkins,et al. Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK , 2021, Frontiers in Medicine.
[32] G. Wogan,et al. Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset , 2021, Proceedings of the National Academy of Sciences.
[33] G. Rodger,et al. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.
[34] G. Gao,et al. Viral targets for vaccines against COVID-19 , 2020, Nature reviews. Immunology.
[35] K. Stirrups,et al. A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital , 2020, Journal of Infection.
[36] M. Blaser,et al. Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospital Workers: Results From a Screening Study in New Jersey, United States in Spring 2020 , 2020, Open forum infectious diseases.
[37] S. Ciesek,et al. Analysis of humoral immune responses in SARS-CoV-2 infected patients , 2020, The Journal of infectious diseases.
[38] C. Cordon-Cardo,et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.
[39] Lars G. Fritsche,et al. Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System , 2020, JAMA network open.
[40] G. Chertow,et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study , 2020, The Lancet.
[41] M. Veldhoen,et al. Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset , 2020, medRxiv.
[42] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[43] C. Hillyer,et al. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses , 2020, Trends in Immunology.
[44] Yaokai Chen,et al. Patterns of IgG and IgM antibody response in COVID-19 patients , 2020, Emerging microbes & infections.
[45] P. Neven,et al. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy , 2019, Breast Cancer Research and Treatment.
[46] M. Mottolese,et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study , 2008, Breast Cancer Research.